UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ FORM 10-Q ____________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 29, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ...

Exhibit 99.1 November 7, 2024 QuidelOrtho Reports Third Quarter 2024 Financial Results ― Company reinstates 2024 financial guidance ― ― Drives cost-savings and growth initiatives ― ― Strengthens leadership team and aligns organization for improved effectiveness ― Third Quarter 2024 Results and Recent Developments (all comparisons are to the prior year period) • Reported revenue was $727 million ◦ Recurring revenue was $598 million as reported with no significant change in constant currency, excluding COVID- ...

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of QuidelOrtho Corporation (NASDAQ: QDEL) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, QuidelOrtho insiders caused the company to misrepresent or fail to disclose that (a) QuidelOrtho sold more COVID-19 tests to its distributors and pharmacy chain customers than they could resell to healthcare providers and end ...

QuidelOrtho Corporation (QDEL) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid first-half 2024 performance and its continued spending on research and development (R&D), is expected to contribute further. However, headwinds due to data security threats and reimbursement policies persist. This Zacks Rank #3 (Hold) company has lost 42.6% year to date against 12.4% growth of the industry. The S&P 500 has witnessed 18.5% growth in the said ...

QuidelOrtho Corporation (QDEL) recently announced the FDA 510(k) clearance for its VITROS syphilis assay as part of its menu, which is likely to strengthen its position as a leader in infectious disease testing. The expansion into the U.S. market aims to provide timely and accurate diagnosis, crucial for effective treatment and control of the disease. With this latest development, QDEL's shares are likely to witness a northward movement. More on QDEL's VITROS Syphilis Assay The VITROS syphilis assay is desi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ FORM 10-Q ____________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 9975 Summers Ridge Road, San Diego, ...

QuidelOrtho Corporation (QDEL) reported an adjusted loss per share of 7 cents in the second quarter of 2024 against earnings per share (EPS) of 26 cents in the year-ago period. However, the figure beat the Zacks Consensus Estimate by 66.7%. The adjustments include expenses related to the amortization of intangibles, and acquisition and integration costs, among others. GAAP loss per share in the quarter was $2.20 compared with 80 cents in the year-ago quarter. Revenues in Detail QuidelOrtho registered revenu ...

QuidelOrtho Corporation (NASDAQ:QDEL) Q2 2024 Earnings Conference Call July 31, 2024 5:00 PM ET Company Participants Juliet Cunningham - Vice President-Investor Relations Brian Blaser - President & Chief Executive Officer Joe Busky - Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research Casey Woodring - JPMorgan Patrick Donnelly - Citi Andrew Cooper - Raymond James Operator Welcome to the QuidelOrtho Second Quarter 2024 Financial Results Conference Call and Webcast. At this tim ...

QuidelOrtho (QDEL) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to earnings of $0.26 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 66.67%. A quarter ago, it was expected that this medical diagnostics company would post earnings of $0.43 per share when it actually produced earnings of $0.44, delivering a surprise of 2.33%. Over the last four quarters, ...

Exhibit 99.1 July 31, 2024 QuidelOrtho Reports Second Quarter 2024 Financial Results — $100 million in annualized cost-savings initiatives will benefit second half 2024 and first half 2025 — — Strong progress on business review and refocusing R&D investments on core growth areas — Second quarter 2024 revenue was $637 million, as reported: • Total recurring revenue grew 3% as reported and 5% in constant currency compared to the prior year period, excluding COVID-19 revenue and U.S. Donor Screening revenue 1 ...